Dev Prasad
Stock Analyst at Lucid Capital
(4.71)
# 642
Out of 4,362 analysts
15
Total ratings
71.4%
Success rate
92.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dev Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QNRX Quoin Pharmaceuticals | Initiated Coverage: Buy | $30 | $4.43 | +577.20% | 1 | May 4, 2026 | |
| ABOS Acumen Pharmaceuticals | Initiated Coverage: Buy | $6 | $2.29 | +162.01% | 1 | Dec 17, 2025 | |
| PVLA Palvella Therapeutics | Maintained: Buy | $49 → $212 | $115.42 | +83.68% | 2 | Dec 15, 2025 | |
| IFRX InflaRx | Maintained: Buy | $24 | $2.06 | +1,065.05% | 1 | Nov 10, 2025 | |
| VRCA Verrica Pharmaceuticals | Initiated Coverage: Buy | $19 | $5.87 | +223.68% | 1 | Nov 5, 2025 | |
| TSX: MDNA Medicenna Therapeutics Corp. | Initiated Coverage: Buy | $4.00 | $0.455 | +779.12% | 1 | Oct 14, 2025 | |
| ATYR aTyr Pharma | Downgraded: Hold | $1 | $0.5001 | +99.96% | 1 | Sep 15, 2025 | |
| CUE Cue Biopharma | Initiated Coverage: Buy | $4 | $26.91 | -85.14% | 1 | Aug 25, 2025 | |
| IRD Opus Genetics | Initiated Coverage: Buy | $5 | $4.20 | +19.05% | 1 | Jun 17, 2025 | |
| EDSA Edesa Biotech | Initiated Coverage: Buy | $9 | $6.86 | n/a | 1 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $36 | $5.14 | n/a | 1 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $6 | $1.84 | n/a | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $24 | $13.74 | n/a | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $13 | $0.8502 | n/a | 1 | Dec 17, 2024 |
Quoin Pharmaceuticals
May 4, 2026
Initiated Coverage: Buy
Price Target: $30
Current: $4.43
Upside: +577.20%
Acumen Pharmaceuticals
Dec 17, 2025
Initiated Coverage: Buy
Price Target: $6
Current: $2.29
Upside: +162.01%
Palvella Therapeutics
Dec 15, 2025
Maintained: Buy
Price Target: $49 → $212
Current: $115.42
Upside: +83.68%
InflaRx
Nov 10, 2025
Maintained: Buy
Price Target: $24
Current: $2.06
Upside: +1,065.05%
Verrica Pharmaceuticals
Nov 5, 2025
Initiated Coverage: Buy
Price Target: $19
Current: $5.87
Upside: +223.68%
Medicenna Therapeutics Corp.
Oct 14, 2025
Initiated Coverage: Buy
Price Target: $4.00
Current: $0.455
Upside: +779.12%
aTyr Pharma
Sep 15, 2025
Downgraded: Hold
Price Target: $1
Current: $0.5001
Upside: +99.96%
Cue Biopharma
Aug 25, 2025
Initiated Coverage: Buy
Price Target: $4
Current: $26.91
Upside: -85.14%
Opus Genetics
Jun 17, 2025
Initiated Coverage: Buy
Price Target: $5
Current: $4.20
Upside: +19.05%
Edesa Biotech
May 23, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $6.86
Upside: n/a
May 1, 2025
Initiated Coverage: Buy
Price Target: $36
Current: $5.14
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $6
Current: $1.84
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $24
Current: $13.74
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $13
Current: $0.8502
Upside: n/a